COLO-B.CO vs. NVO

In the year-to-date period, COLO-B.CO achieves a 1.32% return, which is significantly higher than NVO's -9.47% return. Over the past 10 years, COLO-B.CO has underperformed NVO with an annualized return of 7.21%, while NVO has yielded a comparatively higher 15.51% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Coloplast A/S (COLO-B.CO) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current COLO-B.CO Sharpe Ratio is -0.33, which is higher than the NVO Sharpe Ratio of -0.92. The chart below compares the historical Sharpe Ratios of COLO-B.CO and NVO, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

COLO-B.CO's dividend yield for the trailing twelve months is around 2.76%, more than NVO's 1.85% yield.

The maximum COLO-B.CO drawdown since its inception was -43.67%, smaller than the maximum NVO drawdown of -71.32%. Use the drawdown chart below to compare losses from any high point for COLO-B.CO and NVO. For additional features, visit the drawdowns tool.

The current volatility for Coloplast A/S (COLO-B.CO) is 5.90%, while Novo Nordisk A/S (NVO) has a volatility of 13.24%. This indicates that COLO-B.CO experiences smaller price fluctuations and is considered to be less risky than NVO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Coloplast A/S and Novo Nordisk A/S. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.